Hall A |
Tuesday, 6 May 2014 |
13.00 - 14.30 |
ASTRA ZENECA VACCINATING CHILDREN AGAINST INFLUENZA – UPDATE ON
RECENT CHANGES IN EUROPE |
15.00 - 16.30 |
GSK PUBLIC HEALTH STRATEGIES TO PREVENT BACTERIAL DISEASES IN CHILDHOOD |
Wednesday, 7 May 2014 |
08.45 - 10.15 |
SANOFI PASTEUR MSD IMPROVING IMPLEMENTATION OF VACCINATION PROGRAMS |
10.45 - 12.15 |
ABBVIE THE ONGOING GLOBAL CHALLENGE OF RSV INFECTION: EMERGING INTERVENTIONS AGAINST RSV |
13.00 - 14.30 |
GSK CERVARIX® 2-DOSE SCHEDULE*: A NEW CHAPTER IN CERVICAL CANCER PREVENTION PROSPECTS OF A REDUCED SCHEDULE IN HPV VACCINATION |
15.00 - 16.30 |
NOVARTIS VACCINES TRANSFORMING THE LANDSCAPE OF MENINGOCOCCAL DISEASE PREVENTION |
16.50 - 18.20 |
PFIZER PNEUMOCOCCAL VACCINATION: WHERE WE ARE AND WHERE WE ARE GOING |
TUESDAY, MAY 6, 2014

VACCINATING CHILDREN AGAINST INFLUENZA – UPDATE ON RECENT CHANGES IN EUROPE
13:00 - 14:30
Chairperson: R. Belshe, USA
13:00–13:10 WELCOME AND INTRODUCTION
R. Belshe, USA, Chair
13:10–13:30 PAEDIATRIC INFLUENZA IMMUNISATION POLICY – THE NORDIC PERSPECTIVE
T. Kilpi, Finland
13:30–13:50 EFFECTIVENESS DATA AND POLICY UPDATE FROM GERMANY
M. Rose, Germany
13:50–14:15 THE 2013/14 UK (SCOTLAND) CHILDHOOD VACCINATION PROGRAMME – HOW
DID IT GO?
J. McMenamin, UK
14:15–14:30 QUESTIONS AND PANEL
Discussion led by R. Belshe, Chair
*************************************************************************

PUBLIC
HEALTH STRATEGIES TO PREVENT BACTERIAL DISEASES IN CHILDHOOD
15:00-16:30
15:00 – 15:10 WELCOME AND INTRODUCTION
M. Slack, UK
15:10 – 15:30 STRATEGIES TO HELP PROTECT AGAINST MENINGOCOCCAL DISEASES
V. Papaevangelou, Greece
15:30 – 15:50 LESSONS LEARNT FROM PNEUMOCOCCAL VACCINATION PROGRAMMES
A. Palmu, Finland
15:50 – 16:10 PERTUSSIS: WHY DO WE NEED A LIFE-LONG STRATEGY?
C. Wirsing von Koenig, Germany
16:10 – 16:20 CONCLUDING REMARKS
M.Slack, UK
16:20 – 16:30 Q&A
WEDNESDAY, MAY 7, 2014

IMPROVING IMPLEMENTATION OF VACCINATION PROGRAMS
8:45 - 10:15
Chair: Prof. Ulrich Heininger
ROUTINE PAEDIATRIC VACCINATION IN EUROPE. SUCCESS AND CHALLENGES
U. Heininger
A NEW HEXAVALENT VACCINE UP TO CURRENT TIMES' EXPECTATIONS
F. Martinon-Torres
INTRODUCTION OF MMR/V VACCINES IN EU CHILDHOOD VACCINATION PROGRAMS
C. Giaquinto
HPV VACCINATION IN PRE-TEENS AND TEENS: INFORMATION, CHECK-UP AND CATCH-UP
C. Weil-Olivier
*************************************************************************

THE ONGOING GLOBAL CHALLENGE OF RSV INFECTION: EMERGING INTERVENTIONS AGAINST RSV
10:45– 12:15
10:45-10:50 WELCOME AND INTRODUCTION
Eleanor Molloy
10:50-11:15 NOVEL INSIGHTS IN RSV PATHOGENESIS, PREVENTION AND TREATMENT
Louis Bont
11:15-11:40 THE DEVELOPMENT OF THE PRETERM NEONATAL IMMUNE SYSTEM AND NEW
EVIDENCE ON THE ROLE OF VITAMIN D
Eleanor Molloy
11:40-12:05 ADVANCES IN RSV VACCINE DEVELOPMENT
Barnie Graham
12:05-12:15 Q&A
*************************************************************************

CERVARIX® 2-DOSE SCHEDULE*: A NEW CHAPTER IN CERVICAL CANCER PREVENTION
PROSPECTS OF A REDUCED SCHEDULE IN HPV VACCINATION
13.00 - 14.30
Moderator:
Mark Porter UK
Participants:
M. Van Ranst Belgium
C. Dannecker Germany
T. Schwarz Germany
C. Weil-Olivier, France
13:00–13:05 HPV AND CERVICAL CANCER – VIDEO
13:05–13:10 WELCOME AND INTRODUCTION
13:10–14:15 SHORT PRESENTATIONS AND ROUNDTABLE DISCUSSION ON FOLLOWING
TOPICS:
- Incidence of cervical cancer
- Prevention of cervical cancer through screening and vaccination
- HPV vaccination compliance and coverage
- Cervical cancer and its treatments
- Introduction of Cervarix® 2-dose vaccination schedule* and results of clinical trials
- Immunise today to protect later: the role of paediatricians in vaccination of young adolescent girls
14:15–14:25 Q&A
14:25–14:30 CONCLUSIONS
* Cervarix® 2-dose vaccination schedule is registered for 9-14 years old girls
*************************************************************************

TRANSFORMING THE LANDSCAPE OF MENINGOCOCCAL DISEASE PREVENTION
15:00–16:30
15:00–15:10 WELCOME AND OPENING
A Nicholson, Programme Co-Chair
15:10–15:25 EPIDEMIOLOGY OF MENINGOCOCCAL DISEASE: ASSESSING AN UNPREDICTABLE
BURDEN
S. Black
15:25–15:40 THE POTENTIAL LONG-TERM IMPLICATIONS OF SURVIVING MENINGOCOCCAL
DISEASE
S. Nadel
15:40–16:00 BREAKING BARRIERS IN THE FIGHT AGAINST MENINGOCOCCAL SEROGROUP B
DISEASE
F. Martinón-Torres
16:00–16:20 UNDERSTANDING PARENTAL ACCEPTANCE OF NEW VACCINES
W. Fisher
16:20–16:30 Q&A AND CLOSING REMARKS
R. Rappuoli, Programme Co-Chair
*************************************************************************
For information, visit our booth.
PNEUMOCOCCAL VACCINATION: WHERE WE ARE AND WHERE WE ARE GOING
16:50-18:20
Chair: K. Connolly, Ireland
Co-chair: H.Schmitt, France
16:50 WELCOME AND INTRODUCTION
K. Connolly, Ireland
H.Schmitt, France
17:00 THE BENEFITS OF PCV13 - WHERE WE ARE TODAY
R. Sâ-Leâo, Portugal
17:20 CLINICAL PRACTICE IN THE ERA OF PNEUMOCOCCAL CONJUGATE VACCINATION
I. De Schutter, Belgium
17:40 VACCINES FOR THE FUTURE – WHAT ARE THE CHALLENGES?
U. Heininger, Switzerland
18:00 Q&A AND CLOSURE
K. Connolly, Ireland
H. Schmitt, France